Inspira Technologies OXY B.H.N. (IINN) Expected to Release Earnings on Thursday

Inspira Technologies OXY B.H.N. (NASDAQ:IINN) will likely be announcing its results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of ($0.03) per share and revenue of $15.00 million for the quarter.

Inspira Technologies OXY B.H.N. Price Performance

Shares of NASDAQ IINN opened at $0.90 on Tuesday. Inspira Technologies OXY B.H.N. has a fifty-two week low of $0.34 and a fifty-two week high of $1.65. The company has a current ratio of 1.56, a quick ratio of 1.30 and a debt-to-equity ratio of 0.08. The business’s 50 day moving average price is $1.59 and its 200-day moving average price is $0.93.

Hedge Funds Weigh In On Inspira Technologies OXY B.H.N.

An institutional investor recently bought a new stake in Inspira Technologies OXY B.H.N. stock. Kestra Advisory Services LLC purchased a new stake in shares of Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 78,824 shares of the company’s stock, valued at approximately $71,000. 12.72% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Inspira Technologies OXY B.H.N. in a research report on Friday, April 10th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Inspira Technologies OXY B.H.N. has a consensus rating of “Sell”.

Inspira Technologies OXY B.H.N. Company Profile

Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation for the treatment of acute respiratory failure. Its lead product is the augmented respiration technology system, a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels.